NCT04987996 2023-06-06GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer PatientsProvidence Health & ServicesPhase 2 Withdrawn
NCT02575404 2023-06-05GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsProvidence Health & ServicesPhase 1 Completed36 enrolled